India’s pharmaceutical and healthcare industry experienced a remarkable resurgence in the third quarter of 2025, recording USD 3.5 billion (approximately Rs. 29,000 crore) in deal value across 72 transactions. The period marked a strong rebound driven by mergers and acquisitions (M&A), private equity participation, and a series of high-value public market offerings.